pyrazines has been researched along with Leukemia, Lymphoblastic, Acute, T Cell in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiba, S; Furukawa, Y; Hiraoka, N; Kikuchi, J; Koyama, D; Kurosawa, H; Wada, T | 1 |
| Abbenante, MC; Derenzini, E; Ferrari, A; Ghelli Luserna Di Rorà, A; Guadagnuolo, V; Iacobucci, I; Imbrogno, E; Martinelli, G; Paolini, S; Papayannidis, C; Parisi, S; Robustelli, V; Sartor, C | 1 |
| Alves, G; Bigni, R; de Andrade, CF; Pereira, DA; Pombo-de-Oliveira, MS | 1 |
| Badowska, W; Czyzewski, K; Juraszewska, E; Konatkowska, B; Kuzmicz, M; Malinowska, I; Olejnik, I; Pogorzala, M; Sobol, G; Stanczak, E; Stefaniak, J; Styczynski, J; Szczepanek, J; Szczepanski, T; Wysocki, M | 1 |
| Hawley, RG; Hawley, TS; Riz, I; Toma, I; Zweier-Renn, LA | 1 |
| Guo, F; He, G; Hu, X; Shen, Y; Sun, A; Xu, J | 1 |
| Assaraf, YG; Chan, ET; Cloos, J; Franke, NE; Geerke, DP; Jansen, G; Kaspers, GJ; Kirk, CJ; Niewerth, D; Schimmer, AD; van Meerloo, J; van Zantwijk, CH; Vojtekova, K; Zweegman, S | 1 |
| Cheng, H; Hu, X; Huang, C; Lü, S; Song, X; Wang, J; Wang, L; Yang, J | 1 |
| Belitsky, G; Budunova, I; Gordon, LI; Kirsanov, K; Lesovaya, E; Popa, A; Rosen, ST; Yakubovskaya, M; Yemelyanov, A | 1 |
9 other study(ies) available for pyrazines and Leukemia, Lymphoblastic, Acute, T Cell
| Article | Year |
|---|---|
Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
Topics: Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Chromatin Immunoprecipitation; Core Binding Factor Alpha 3 Subunit; Drug Resistance, Neoplasm; Humans; Mice; Mice, Inbred NOD; Mice, SCID; NF-kappa B; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Real-Time Polymerase Chain Reaction; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured | 2014 |
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.
Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Checkpoint Kinase 2; Clofarabine; Dasatinib; Drug Synergism; Humans; Imatinib Mesylate; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazines; Pyrazoles | 2016 |
CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia.
Topics: Adolescent; Cell Membrane; Child; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Kinetics; Lymphocyte Activation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Reference Values; Sitagliptin Phosphate; Triazoles; Young Adult | 2009 |
Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia.
Topics: Adolescent; Antineoplastic Agents; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines | 2010 |
Apoptotic role of IKK in T-ALL therapeutic response.
Topics: Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-myc; Pyrazines; Receptor, Notch1; Signal Transduction; Vincristine | 2011 |
Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-κB activity.
Topics: Adolescent; Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; NF-kappa B; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protease Inhibitors; Pyrazines; Treatment Outcome | 2011 |
Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Topics: Amino Acid Substitution; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Mutation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2012 |
Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mice; Mice, Nude; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Dimerization; Drug Synergism; Hematologic Neoplasms; Humans; K562 Cells; Lymphoma; NF-kappa B; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Receptors, Glucocorticoid; RNA Interference; RNA, Small Interfering; Transcription Factor AP-1; Transcriptional Activation; Triazoles; Tumor Cells, Cultured | 2013 |